Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective

Bone Marrow Transplantation

Volumn 31, Issue 2, 2003, Pages 99-103

  Bargetzi, M J ^a   Passweg, J ^b   Baertschi, E ^a   Schoenenberger, A ^a   Gwerder, C ^a   Tichelli, A ^b   Burger, J ^a   Mingrone, W ^a   Herrmann, R ^b   Gratwohl, A ^b   Wernli, M ^a  

^a Kantonsspital Aarau   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

G CSF; Multiple myeloma; PBSC mobilization; Vinorelbine

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; NAVELBINE; PREDNISOLONE; VINCRISTINE;

ACCURACY; ADULT; AGED; APHERESIS; CANCER RADIOTHERAPY; CANCER STAGING; CELL COUNT; CELL SELECTION; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEMATOPOIESIS; HUMAN; MALE; MULTIPLE MYELOMA; OUTPATIENT CARE; PATIENT CARE; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELIABILITY; REVIEW; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT;

AGED; ANTIGENS, CD; ANTIGENS, CD34; COST-BENEFIT ANALYSIS; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; SWITZERLAND; VINBLASTINE;

EID: 0242515840     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703787     Document Type: Review

References (18)

1. Barlogie B, Alexanian R, Dicke K et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872.
2. Fermand J-P, Chevret S, Ravaud P et al. High-dose chemoradiotherapy and autologous stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood 1993; 82: 2005-2009.
3. Harousseau J, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
4. Attal M, Harousseau J-L, Stoppa A-M et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
5. Deskin R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
6. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-447.
7. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
8. Boiron JM, Marit G, Faberes C et al. Collection of peripheral blood stem cells in multiple myeloma with and without recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF). Bone Marrow Transplant 1993; 12: 49-55.
9. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
10. Deskin R, Barlogie B, Sundar J et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547-1553.
11. Harousseau JL, Maloisel F, Sotto JJ et al. Vinorelbine (VRL) in patients with recurrent multiple myelomas (MM): a phase II study. Proc ASCO 1997; 16: 37 (abstr).
12. Harousseau JL, Dammacco F, San Miguel J et al. An alternative treatment for relapsed/resistant multiple myeloma (MM): Vinorelbine (VRL), plus high-dose dexamethasone (DEX): two phase II studies. Proc ASCO 1999; 18: 107 (abstr).
13. Magagnoli M, Sarina B, Balzarotti M et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001; 28: 923-927.
14. Durie B, Salmon S. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-852.
15. Mohle R, Murea S, Pforsich M et al. Estimation of the progenitor cell yield in a leukapheresis product by previous measurement of CD34+ cells in the peripheral blood. Vox Sanguinis 1996; 71: 90-96.
16. Morrison A-E, Green R-H-A, Watson D et al. Measurement of peripheral blood CD34 counts to optimise the timing of peripheral blood progenitor cell (PBPC) collections for autologous transplants. Br J Haematol 1997; 97 (Suppl 1): 41.
17. Barnett D, Janossy A, Lubenko A et al. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Clin Lab Haem 1999; 21: 301-308.
18. Tichelli A, Gratwohl A, Bargetzi M et al. Autologe Transplantation von hämopoietischen Vorläuferzellen nach CD34-Anreicherung. Schweiz Med Wochenschr 1996; 126: 201-206.